Etcembly is at the forefront of developing innovative immunotherapies through the integration of artificial intelligence (AI) and experimental validation. Their proprietary technology, EMLy™, is a leading repertoire decoding platform specifically designed for T-cell receptors (TCRs), antibodies, and bispecifics. This multi-modality platform employs advanced protein language models that are adaptable across various diseases and therapeutic needs. By leveraging AI-driven insights, Etcembly aims to enhance drug discovery outcomes, delivering safer and more precise drug candidates at an accelerated pace. Their approach includes rapid design and engineering of new candidates, optimizing TCRs and antibodies, and utilizing deep sequencing to improve immune repertoire accuracy.

The company also emphasizes the importance of collaboration with long-term cancer survivors to uncover novel therapeutic targets. Through their Long-term Cancer Survivor Study, Etcembly investigates the immune repertoires of patients who have successfully undergone immunotherapy, aiming to identify new TCRs and antibodies that can be harnessed for future treatments. Their commitment to combining machine intelligence with human expertise positions them as a leader in the field of precision medicine, ultimately striving to meet the urgent needs of cancer patients through tailored immunotherapy solutions.

United Kingdom

Etcembly’s vision is to decode immune repertoires for health and disease.

The TCR repertoire holds the answers to therapeutics and biomarker information, and Etcembly is assembling the world’s largest health and disease immune database, to revolutionise immunotherapy and personalised therapeutics across all patient groups, globally.

We are pushing the frontiers to explore the intersection between immunology and machine learning.

Etcembly

Company Details